Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65


Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations.

Cunanan KM, Koopmeiners JS.

Contemp Clin Trials. 2018 Jun 21;71:162-172. doi: 10.1016/j.cct.2018.06.012. [Epub ahead of print]


Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate.

Jin J, Zhang L, Leng E, Metzger GJ, Koopmeiners JS.

Stat Med. 2018 Jun 19. doi: 10.1002/sim.7810. [Epub ahead of print]


Age Moderates Smokers' Subjective Response to Very Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial.

Cassidy RN, Tidey JW, Cao Q, Colby SM, McClernon FJ, Koopmeiners JS, Hatsukami D, Donny EC.

Nicotine Tob Res. 2018 Apr 28. doi: 10.1093/ntr/nty079. [Epub ahead of print]


Development of a measure for evaluating lesion-wise performance of CAD algorithms in the context of mpMRI detection of prostate cancer.

Leng E, Spilseth B, Zhang L, Jin J, Koopmeiners JS, Metzger GJ.

Med Phys. 2018 May;45(5):2076-2088. doi: 10.1002/mp.12861. Epub 2018 Apr 16.


A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies.

Kaizer AM, Hobbs BP, Koopmeiners JS.

Biometrics. 2018 Jan 22. doi: 10.1111/biom.12841. [Epub ahead of print]


A multiplex platform for the identification of ovarian cancer biomarkers.

Boylan KLM, Geschwind K, Koopmeiners JS, Geller MA, Starr TK, Skubitz APN.

Clin Proteomics. 2017 Oct 10;14:34. doi: 10.1186/s12014-017-9169-6. eCollection 2017.


Bayesian hierarchical modeling based on multisource exchangeability.

Kaizer AM, Koopmeiners JS, Hobbs BP.

Biostatistics. 2018 Apr 1;19(2):169-184. doi: 10.1093/biostatistics/kxx031.


Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Pacek LR, Joseph McClernon F, Denlinger-Apte RL, Mercincavage M, Strasser AA, Dermody SS, Vandrey R, Smith TT, Nardone N, Hatsukami DK, Koopmeiners JS, Kozink RV, Donny EC.

Tob Control. 2018 Jul;27(4):420-426. doi: 10.1136/tobaccocontrol-2017-053689. Epub 2017 Jul 22.


Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.

Boatman JA, Vock DM, Koopmeiners JS, Donny EC.

Biostatistics. 2018 Jan 1;19(1):103-118. doi: 10.1093/biostatistics/kxx029.


Hierarchical models for sharing information across populations in phase I dose-escalation studies.

Cunanan KM, Koopmeiners JS.

Stat Methods Med Res. 2017 Jan 1:962280217703812. doi: 10.1177/0962280217703812. [Epub ahead of print]


The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.

Koopmeiners JS, Wey A.

J Biopharm Stat. 2017;27(6):1028-1042. doi: 10.1080/10543406.2017.1293076. Epub 2017 Mar 25.


Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Murphy SE, Sipe CJ, Choi K, Raddatz LM, Koopmeiners JS, Donny EC, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1093-1099. doi: 10.1158/1055-9965.EPI-16-0920. Epub 2017 Mar 6.


Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study.

Borgatti A, Winter AL, Stuebner K, Scott R, Ober CP, Anderson KL, Feeney DA, Vallera DA, Koopmeiners JS, Modiano JF, Froelich J.

PLoS One. 2017 Feb 21;12(2):e0172651. doi: 10.1371/journal.pone.0172651. eCollection 2017.


Checkpoints for Preliminary Identification of Small Molecules found Enriched in Autophagosomes and Activated Mast Cell Secretions Analyzed by Comparative UPLC/MSe.

Satori CP, Ramezani M, Koopmeiners JS, Meyer AF, Rodriguez-Navarro JA, Kuhns MM, Taylor TH, Haynes CL, Dalluge JJ, Arriaga EA.

Anal Methods. 2017;9(1):46-54. doi: 10.1039/C6AY02500E. Epub 2016 Oct 11.


Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA.

Mol Cancer Ther. 2017 May;16(5):956-965. doi: 10.1158/1535-7163.MCT-16-0637. Epub 2017 Feb 13.


Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes.

Rupprecht LE, Koopmeiners JS, Dermody SS, Oliver JA, al'Absi M, Benowitz NL, Denlinger-Apte R, Drobes DJ, Hatsukami D, McClernon FJ, Pacek LR, Smith TT, Sved AF, Tidey J, Vandrey R, Donny EC.

Tob Control. 2017 Mar;26(e1):e43-e48. doi: 10.1136/tobaccocontrol-2016-053301. Epub 2016 Nov 17.


A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D.

N Engl J Med. 2016 Oct 13;375(15):1448-1456.


Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.

Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC.

Nicotine Tob Res. 2017 Jan;19(1):59-67. Epub 2016 Aug 3.


Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Pacek LR, Vandrey R, Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC.

Drug Alcohol Depend. 2016 Oct 1;167:228-32. doi: 10.1016/j.drugalcdep.2016.08.620. Epub 2016 Aug 28.


Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.

Koopmeiners JS, Hobbs BP.

Stat Methods Med Res. 2018 May;27(5):1547-1558. doi: 10.1177/0962280216665418. Epub 2016 Sep 1.


A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.

Cunanan KM, Koopmeiners JS.

Stat Med. 2017 Jan 15;36(1):43-53. doi: 10.1002/sim.7087. Epub 2016 Aug 21.


Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.

Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL.

Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.


Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Denlinger RL, Smith TT, Murphy SE, Koopmeiners JS, Benowitz NL, Hatsukami DK, Pacek LR, Colino C, Cwalina SN, Donny EC.

Tob Regul Sci. 2016 Apr;2(2):186-203. doi: 10.18001/TRS.2.2.9.


Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.

Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr.

J Infect Dis. 2016 Jun 15;213(12):1906-13. doi: 10.1093/infdis/jiw061. Epub 2016 Feb 11.


Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.

Skubitz KM, Geschwind K, Xu WW, Koopmeiners JS, Skubitz AP.

J Transl Med. 2016 Feb 13;14:51. doi: 10.1186/s12967-016-0802-3.


Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology.

Metzger GJ, Kalavagunta C, Spilseth B, Bolan PJ, Li X, Hutter D, Nam JW, Johnson AD, Henriksen JC, Moench L, Konety B, Warlick CA, Schmechel SC, Koopmeiners JS.

Radiology. 2016 Jun;279(3):805-16. doi: 10.1148/radiol.2015151089. Epub 2016 Jan 29.


mHealth Pilot Study: Text Messaging Intervention to Promote HPV Vaccination.

Lee HY, Koopmeiners JS, McHugh J, Raveis VH, Ahluwalia JS.

Am J Health Behav. 2016 Jan;40(1):67-76. doi: 10.5993/AJHB.40.1.8.


Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking.

Konorev D, Koopmeiners JS, Tang Y, Franck Thompson EA, Jensen JA, Hatsukami DK, Turesky RJ.

Chem Res Toxicol. 2015 Dec 21;28(12):2390-9. doi: 10.1021/acs.chemrestox.5b00401. Epub 2015 Dec 3.


Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.

Koopmeiners JS, Feng Z.

Stat Med. 2016 Apr 15;35(8):1267-80. doi: 10.1002/sim.6790. Epub 2015 Nov 4.


Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermody SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK.

N Engl J Med. 2015 Oct;373(14):1340-9. doi: 10.1056/NEJMsa1502403.


Compensatory smoking from gradual and immediate reduction in cigarette nicotine content.

Hatsukami DK, Donny EC, Koopmeiners JS, Benowitz NL.

Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):472-6. doi: 10.1158/1055-9965.EPI-14-0739. Epub 2014 Dec 16.


Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention.

Lee HY, Koopmeiners JS, Rhee TG, Raveis VH, Ahluwalia JS.

J Med Internet Res. 2014 Aug 27;16(8):e196. doi: 10.2196/jmir.3576.


Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.

Cunanan K, Koopmeiners JS.

BMC Med Res Methodol. 2014 Apr 14;14:51. doi: 10.1186/1471-2288-14-51.


Evaluation of protein biomarkers of prostate cancer aggressiveness.

Rizzardi AE, Rosener NK, Koopmeiners JS, Isaksson Vogel R, Metzger GJ, Forster CL, Marston LO, Tiffany JR, McCarthy JB, Turley EA, Warlick CA, Henriksen JC, Schmechel SC.

BMC Cancer. 2014 Apr 5;14:244. doi: 10.1186/1471-2407-14-244.


Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors.

Rizzardi AE, Vogel RI, Koopmeiners JS, Forster CL, Marston LO, Rosener NK, Akentieva N, Price MA, Metzger GJ, Warlick CA, Henriksen JC, Turley EA, McCarthy JB, Schmechel SC.

Cancer. 2014 Jun 15;120(12):1800-9. doi: 10.1002/cncr.28646. Epub 2014 Mar 25.


Sample size and screening size trade-off in the presence of subgroups with different expected treatment effects.

Rudser KD, Bendert E, Koopmeiners JS.

J Biopharm Stat. 2014;24(2):344-58. doi: 10.1080/10543406.2013.860154.


Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity.

Misemer BS, Skubitz AP, Carlos Manivel J, Schmechel SC, Cheng EY, Henriksen JC, Koopmeiners JS, Corless CL, Skubitz KM.

Cancer Med. 2014 Feb;3(1):81-90. doi: 10.1002/cam4.160. Epub 2013 Nov 26.


High expression of class III β-tubulin in small cell lung carcinoma.

Powell S, Kaizer A, Koopmeiners JS, Iwamoto C, Klein M.

Oncol Lett. 2014 Feb;7(2):405-410. Epub 2013 Dec 6.


Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.

Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, Ryu Y, Goldberg JE, Schmechel SC, Koopmeiners JS, McCarthy JB, Schwertfeger KL.

Cancer Res. 2014 Jan 1;74(1):374-86. doi: 10.1158/0008-5472.CAN-13-2469. Epub 2013 Nov 6.


A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.

Koopmeiners JS, Modiano J.

Clin Trials. 2014 Feb;11(1):38-48. doi: 10.1177/1740774513500589. Epub 2013 Sep 30.


Trends in pneumonia hospitalizations in Hennepin County, Minnesota, 1999-2010.

Iroh Tam PY, Koopmeiners JS.

Mayo Clin Proc. 2013 Oct;88(10):1181-2. doi: 10.1016/j.mayocp.2013.08.006. No abstract available.


Kinetics of O(6)-pyridyloxobutyl-2'-deoxyguanosine repair by human O(6)-alkylguanine DNA alkyltransferase.

Kotandeniya D, Murphy D, Yan S, Park S, Seneviratne U, Koopmeiners JS, Pegg A, Kanugula S, Kassie F, Tretyakova N.

Biochemistry. 2013 Jun 11;52(23):4075-88. doi: 10.1021/bi4004952. Epub 2013 May 31.


A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Zhong W, Koopmeiners JS, Carlin BP.

Contemp Clin Trials. 2013 Nov;36(2):587-96. doi: 10.1016/j.cct.2013.03.011. Epub 2013 Apr 11.


Quantitative multiparametric MRI of ovarian cancer.

Carter JS, Koopmeiners JS, Kuehn-Hajder JE, Metzger GJ, Lakkadi N, Downs LS Jr, Bolan PJ.

J Magn Reson Imaging. 2013 Dec;38(6):1501-9. doi: 10.1002/jmri.24119. Epub 2013 Apr 4.


Early termination of a two-stage study to develop and validate a panel of biomarkers.

Koopmeiners JS, Vogel RI.

Stat Med. 2013 Mar 15;32(6):1027-37. doi: 10.1002/sim.5622. Epub 2012 Oct 2.


Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D Hoff.

Carlin BP, Zhong W, Koopmeiners JS.

Clin Trials. 2013 Feb;10(1):81-5; discussion 88-92. doi: 10.1177/1740774512469313. No abstract available.


A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.

Zhong W, Koopmeiners JS, Carlin BP.

Stat Med. 2012 Dec 20;31(29):3885-95. doi: 10.1002/sim.5477. Epub 2012 Jul 16.


Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.

Koopmeiners JS, Feng Z, Pepe MS.

Stat Med. 2012 Feb 28;31(5):420-35. doi: 10.1002/sim.4430. Epub 2012 Jan 12.


Intermediate-term outcomes after renal cryoablation: results of a multi-institutional study.

Duffey B, Nguyen V, Lund E, Koopmeiners JS, Hulbert J, Anderson JK.

J Endourol. 2012 Jan;26(1):15-20. doi: 10.1089/end.2011.0179. Epub 2011 Dec 2.


Sample collection and handling considerations for peptidomic studies in whole saliva; implications for biomarker discovery.

de Jong EP, van Riper SK, Koopmeiners JS, Carlis JV, Griffin TJ.

Clin Chim Acta. 2011 Nov 20;412(23-24):2284-8. doi: 10.1016/j.cca.2011.08.023. Epub 2011 Aug 24.

Supplemental Content

Loading ...
Support Center